Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis

• DOI: 10.4143/crt.2017.005
• Publication Date: 2017-05-23T21:57:26Z
• Authors: Jwa Hoon Kim; Sook Ryun Park; Min-Hee Ryu; Baek-Yeol Ryoo; Kyu-pyo Kim; Beom Su Kim; Moon-Won Yoo; Jeong Hwan Yook; Byung Sik Kim; Jihun Kim; Sun-Ju Byeon; Yoon-Koo Kang
• Keywords: Paraaortic lymph nodes

The purpose of this study was to evaluate the efficacy and safety induction chemotherapy with docetaxel, capecitabine, cisplatin (DXP) plus bevacizumab (BEV) on initially unresectable locally advanced gastric cancer (LAGC) or paraaortic lymph node (PAN) metastatic (GC).Patients LAGC PAN GC received six cycles (60 mg/m2 docetaxel intravenously day 1, 937.5 capecitabine orally twice daily days 1-14, 60 7.5 mg/kg BEV 1 every 3 weeks), followed by conversion surgery. primary endpoint R0 resection rate.Thirty-one patients invasion adjacent organs but without metastasis (n=14, group) regardless (n=17, were enrolled between July 2010 December 2014. Twenty-seven (87.1%) completed cycles. most common grade ≥ toxicities neutropenia (71%), fever/infection (22.6%/3.2%), stomatitis (16.1%). clinical response rates 64.3% (95% confidence interval [CI], 46.6 82.0) 64.5% (LAGC group, 71.4%; 58.8%), respectively. pathological complete regression rate 12.9%. After a median follow-up 44.5 months (range, 39.4 49.7 months), progression-free survival overall 13.1 CI, 8.9 17.3) 38.6 22.0 55.1), respectively.Induction DXP+BEV displayed antitumor activities encouraging manageable toxicity profiles GC.